Indivior PLC (INDV)

Market Cap	4.25B
Revenue (ttm)	1.18B
Net Income (ttm)	124.00M
Shares Out	124.85M
EPS (ttm)	0.98
PE Ratio	34.65
Forward PE	12.11
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,180,266
Open	34.00
Previous Close	33.60
Day's Range	33.52 - 34.32
52-Week Range	7.62 - 34.32
Beta	1.11
Analysts	Strong Buy
Price Target	32.50 (-4.41%)
Earnings Date	Oct 30, 2025

About INDV

Indivior PLC, together with its subsidiaries, develops, manufactures, and sells buprenorphine-based prescription drugs for the treatment of opioid dependence and related disorders in the United States, Europe, Canada, Australia, and internationally. The company develops medicines to treat substance use disorders. Its core marketed products include SUBLOCADE buprenorphine extended-release monthly injections; SUBOXONE Film, a buprenorphine and naloxone sublingual film; SUBOXONE Tablet, a buprenorphine and naloxone sublingual tablet; and SUBUTEX T...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1994
• Employees: 1,051
• Stock Exchange: NASDAQ
• Ticker Symbol: INDV
• Website: https://www.indivior.com

Analyst Summary

According to 4 analysts, the average rating for INDV stock is "Strong Buy." The 12-month stock price target is $32.5, which is a decrease of -4.41% from the latest price.

Price Target

$32.5

(-4.41% downside)

Analyst Consensus: Strong Buy